Supplemental Table 1: Reference tables for Figure 2 - Distribution of COVID-19 associated invasive fungal infections per country. a. COVID-19-associated pulmonary aspergillosis (CAPA), b. COVID-19-associated mucormycosis (CAM), and c. COVID-19-associated *Candida* infections (CAC)

a. CAPA

REFERENCE	NUMBER	COUNTRY	CITY	TIME PERIOD
FERNANDEZ, NB[1]	1	Argentina	Buenos Aires	2020 Apr
BENEDETTI, MF[2]	5	Argentina	Buenos Aires	2020
SASONI, N[3]	1	Argentina	Santa Fe	2020 Mar
SHARMA, A[4]	1	Australia	Liverpool	2020 Apr
PRATTES, J[5,6]	12	Austria	Graz	2020 Mar - 2021 May
VAN ACKERBROECK, S[7]	14	Belgium	Antwerp	2020 Feb - 2021 Mar 31
RUTSAERT, L[8]	7	Belgium	Antwerp	2020 Mar 12 - April 25
JANSSEN, NAF[9]	5	Belgium	Bruges	2020 Feb 28 - May 27
SARRAZYN, C[10]	4	Belgium	Ghent	2020 Mar 11 - Apr 17
PRATTES, J – WAUTERS, J, LAGROU, K[5]	9	Belgium	Leuven	2020 Mar - 2021 May
JANSSEN, NAF[9]	5	Belgium	Roeselare	2020 Feb 28 - May 27
SANTANA, MF[11]	1	Brazil	Manaus	2020
FARIAS, ME[12]	2	Brazil	Manaus	2020 Apr - Jul
DE ALMEIDA, JN JR[13]	14	Brazil	São Paulo	2020 Apr - 2021 Jul
MARTINS, AC[14]	3	Brazil	São Paulo	2020 Feb - Dec
RABAGLIATI, R[15]	9	Chile	Santiago	2020 May - Jul
WANG, J[16]	8	China	Hangzhou	2020 Jan - Mar
FU, Y[17]	1	China	Hangzhou	2019 - 2020 Feb 29
ZHU, X[18]	60	China	Nanjing	2020 Jan 22 - Feb 2
JIANG, Z[19]	8	China	Shenzhen	2020 Jan - Jun
CHEN, N[20]	1	China	Wuhan	2020 Jan 1 - Jan 20
XU, J[21]	78	China	Wuhan	2019 Dec 29 – 2020 Apr 1
YANG, X[22]	2	China	Wuhan	2019 Dec 24 - Jan 26
HAGLUND, A[23]	1	Denmark	Aarhus	2020
HELLEBERG, M[24]	2	Denmark	Copenhagen	2020 Mar 15 - Apr 11
ISMAIEL, WF[25]	6	Egypt	Cairo	2020
ROUZÉ, A[26]	14	Europe	multinational	2020 - 2021
JANSSEN, NAF[9]	7	France	Amiens	2020 Apr 7 - May 31
PRATTES, J – BELLANGER, A-P[5]	1	France	Besancon	2020 Mar - 2021 May
PRATTES, J – DELHAES, L[5]	5	France	Bordeaux	2020 Mar - 2021 May
RAZAZI, K[27]	15	France	Creteil	2019 Dec - 2020 Apr 29
LESCURE, FX[28]	1	France	diverse	2020 Jan 24 - 29
GOUZIEN, L[29]	1	France	Le Chesnay	2020 Mar 1 - Apr 30
JANSSEN, NAF[9]	7	France	Lille	2020 Apr 7 - May 31
DUPONT, D[30]	19	France	Lyon	2020 Mar 1 - Apr 11
FEKKAR, A[31]	6	France	Paris	2020 Mar 6 - Apr 24
GHELFENSTEIN-FERREIRA, T[32]	1	France	Paris	2020
DELLIÈRE, S[33]	21	France	Paris	2020 Mar 15 - May 1
BLAIZE, M[34]	1	France	Paris	2020 Mar

GANGNEUX, JP[35]	7	France	Rennes	2020
REIZINE, F[36]	10	France	Rennes	2020 Mar 3 - Sep 9
JANSSEN, NAF[9]	7	France	Rouen	2020 Apr 7 - May 31
SCHEIN, F[37]	1	France	Saint-Etienne	2020 Mar
VERSYCK, M[38]	2	France	Valenciennes	2020 Mar 15 - Apr 30
ICHAI, P[39]	6	France	Villejuif	2020 Mar 23 - May 4
LEISTNER, R[40]	47	Germany	Berlin	
PRATTES, J – KÖHLER, P[5]	19	Germany	Cologne	2020 Mar - 2021 May
KOEHLER, P[41]	5	Germany	Cologne	2020 Mar 7 - Apr 22
KIRCHHOFF, L[42]	30	Germany	Essen	
ROTHE, K[43]	9	Germany	Munich	2020 Feb 16 - Apr 22
PRATTES, J – LAHMER, T[5]	13	Germany	Munich	2020 Mar - 2021 May
LAHMER, T[44]	2	Germany	Munich	2020
PRATTES, J – STEINMANN, J[5]	5	Germany	Nuremberg	2020 Mar - 2021 May
PRATTES, J – PAUL, G[5]	2	Germany	Stuttgart	2020 Mar - 2021 May
PARAMYTHIOTOU, E[45]	4	Greece	Athens	2020 Mar 22 - Feb 28
NASRI, E[46]	1	Iran	Isfahan	2020 Mar
HAKAMIFARD, A[47]	1	Iran	Isfahan	2020 Jun
GHAZANFARI, M[48]	22	Iran	Sari	2020 May 1 - Sep 30
SALEHI, M[49]	1	Iran	Tehran	2020
ABOLGHASEMI, S[50]	1	Iran	Tehran	2020 Oct
KAKAMAD, FH[51]	1	Iraq	As Sulaymaniyah	2020
MOHAMED, A[52]	1	Ireland	Dublin	2020
BARTOLETTI, M[53]	30	Italy	Bologna	2020 Feb - Apr
SIGNORINI, L[54]	2	Italy	Brescia	2020 Feb 21 - May 6
TROVATO, L[55]	1	Italy	Catania	2020 Oct
PRATTES, J – GIACOBBE, DR, ROBBA, C, PELOSI, P[5]	5	Italy	Genoa	2020 Mar - 2021 May
SALTINI, P[56]	1	Italy	Milan	2021
RIPA, M[57]	11	Italy	Milan	2020 Feb 25 - Apr 6
ANTINORI, S[58]	1	Italy	Milan	2020 Mar
PRATTES, J – VOLPI, S[5]	1	Italy	Modena	2020 Mar - 2021 May
FORTAREZZA, F[59]	9	Italy	Padova	2020 Mar - Jun, 2020 Oct - 2021 Feb
FALCONE, M[60]	1	Italy	Pisa	2020 Mar 4 - Apr 30
OLIVA, A[61]	1	Italy	Rome	2020 Mar - Sep
BRUNO, G[62]	1	Italy	Taranto	2020 Mar
BARATELLA, E[63]	19	Italy	Trieste	2020 Mar - 2021 May
BERLOT, G[64]	1	Italy	Trieste	2021
IWANAGA, Y[65]	1	Japan	Kitakyushu	2021
TAKAZONO, T[66]	10	Japan	National	2020 Jan - 2021 Jan 27
IMOTO, W[67]	1	Japan	Osaka	2020
ALOBAID, K[68]	2	Kuwait	Kuwait City	2020
VELEZ PINTADO, M[69]	16	Mexico	Mexico City	2020 Mar 15 - Jul 10
ROMAN-MONTES, CM[70]	14	Mexico	Mexico City	2020 Apr 13 - Jun 1
VAN SOMEREN GRÉVE, F[71]	1	Netherlands	Amsterdam	2020
VAN BIESEN, S[72]	9	Netherlands	Amsterdam	2020 Apr
JANSSEN, NAF[9]	5	Netherlands	Amsterdam	2020 Feb 28 - May 27

VAN GROOTVELD, R[73]	11	Netherlands	Leiden	2020 Apr 1 - May 11
VAN ARKEL, ALE[74]	6	Netherlands	Leiden	2020 Mar
MEIJER, EFJ[75]	13	Netherlands	Nijmegen	2020 Mar - May, 2020 mid-Sep - mid-Dec
JANSSEN, NAF[9]	5	Netherlands	Rotterdam	2020 Feb 28 - May 27
YUSUF, E[76]	10	Netherlands	Rotterdam	2020 Mar 1 - Apr 21
IQBAL, A[77]	61	Pakistan	Islamabad	2020 Jun - 2021 May
NASIR, N[78]	5	Pakistan	Karachi	2020 Feb - Apr
WACHNICKA-TRUTY, R[79]	1	Poland	Gdansk	2020
RANHEL, D[80]	10	Portugal	Lisbon	2021 Nov - Feb 15
ABDALLA, S[81]	2	Qatar	Doha	2020
TOC, DA[82]	1	Romania	Cluj-Napoca	2020/2021
KLIMKO, N[83]	5	Russia	Saint Petersburg	2020
SHADRIVOVA, O[84]	45	Russia	St. Petersburg	2020 Jun - 2021 May
ALBASATA, H[85]	1	Saudi Arabia	Riyadh	2020 May
MARR, KA[86]	8	Spain	Barcelona	2020 Mar - Jun
GARCIA-VIDAL, C[87]	3	Spain	Barcelona	2020 Feb 28 - Apr 22
SEGRELLES-CALVO, G[88]	7	Spain	Madrid	2020 Feb 1 - Apr 30
PRATTES J – VALERIO, M[5]	12	Spain	Madrid	2020 Mar - 2021 May
MACHADO, M[89]	8	Spain	Madrid	2020 Mar 1 - May 31
FALCES-ROMERO, I[90]	10	Spain	Madrid	2020 Mar - May
BARDI, T[91]	4	Spain	Madrid	2020 Mar - May
TRUJILLO, H[92]	1	Spain	Madrid	2020 Apr
CALDERÓN-PARRA, J[93]	28	Spain	Majadahonda	2020 Mar - 2021 Aug
GARCÍA CLEMENTE, MG[94]	1	Spain	Oviedo	2020
MARTA, GC[95]	35	Spain	Oviedo	2020 Mar 1 - Dec 31
MARTÍN, CS[96]	3	Spain	Valencia	2020 Mar 22 - May 22
NEBREDA-MAYORAL, T[97]	3	Spain	Valladolid	2020 Mar 1 -31
SØGAARD, KK[98]	1	Switzerland	Basel	2020 Feb 25 - May 31
LAMOTH, F[99]	3	Switzerland	Lausanne	2020 Mar 6 - May 11
LU, DE[100]	1	Taiwan	Taipei	2022
CHAUVET, P[101]	6	United Arab Emirates	Abu Dhabi	2020 Mar 24 - May 25
MAES, M[102]	3	United Kingdom	Cambridge	2020 Mar 15 - Aug 30
WHITE, L[103]	19	United Kingdom	Cardiff	2020/2021
HUGHES, S[104]	3	United Kingdom	London	2020 Feb 20 - Apr 20
PRATTES J - RAUTEMAA-RICHARDSON, R[5]	2	United Kingdom	Manchester	2020 Mar - 2021 May
BORMAN, AM[105]	16	United Kingdom	Multicenter	2020 Mar 11 - Jul 14
PRATTES, J – JENKS, J[5]	1	United States	San Diego, California	2020 Mar - 2021 May
WITTING, C[106]	1	United States	Chicago, Illinois	2020
PERMPALUNG, N[107]**/MARR, KA**[86]	39	United States	Multicenter, Maryland	2020 Mar - Aug
WASYLYSHYN, AI[108]	3	United States	Ann Arbor, Michigan	2020 Mar 17 - Oct 5
MITAKA, H[109]	4	United States	New York City, New York	2020 Mar 21 - April 22
PATTI, RK[110]	1	United States	New York City, New York	2020

NASRULLAH, A[111]	1	United States	Pittsburgh, Pennsylvania	2020
STEENWYK, JL[112]	1	United States	Nashville, Tennessee	2020

7 b. CAM

REFERENCE	NUMBER OF CASES	COUNTRY	CITY	TIME PERIOD
ZURL, C[113]	1	Austria	Graz	2020
BASHER, A[114]	1	Bangladesh	Dhaka	2020
PAULI, MA[115]	1	Brazil	Florianopolis	2021
BONATES, P[116]	1	Brazil	Manaus	2020
DO MONTE JR, ES[117]	1	Brazil	Sao Paulo	2020
VENUGOPAL, A[118]	1	Cambodia	Phnom Penh	2021
RABAGLIATI, R[15]	2	Chile	Santiago	2020
ZHU, X[18]	6	China	Nanjing	2020 Jan 22 - Feb 2
HE, Y[119]	2	China	Wuhan	2019 Dec 30 - 2020 Feb 29
LYSKOVA, P[114]	1	Czech Republic	Prague	2021
GEISLER CRONE, C[120]	1	Denmark	Copenhagen	2021
ISMAIEL, WF[25]	10	Egypt	Cairo	2020 Dec
ALFISHAWY, M[121]	21	Egypt	Cairo	2021 Mar 15 - May 15
SAAD, RH[122]	1	Egypt	Cairo	2021
ROUSHDY, T[123]	4	Egypt	Cairo	2021 Jan - Apr
FOUAD, YA[124]	6	Egypt	Cairo	2020 Mar 25 - Sep 25
EL-KHOLY, NH[125]	28	Egypt	Mansoura	2020 Aug - 2020 Dec
RIAD, A[126]	8	Egypt	Multicenter	2021 Apr - May
BELLANGER, A-P[127]	1	France	Besancon	2020
DUPONT, D[30]	1	France	Lyon	2020 Mar 1 - Apr 11
FEKKAR, A[31]	2	France	Paris	2020 Mar 6 - Apr 24
MUNIER, AL & DENIS, B[114]	1	France	Paris	2021
BENHADID-BRAHMI, Y[128]	1	France	Paris	2021
DANION, F[129]	17	France	National	2020 Mar - 2021 Jun 10
SEIDEL, D[130]	13	Germany	Multicenter	2020 Mar - 2021 Jun
SELARKA, L[131]	47	India	Ahmedabad	2021 Jan 3 - Mar 27
DESAI, EJ[132]	100	India	Ahmedabad	2021 Mar - Apr
KUTE, VB[133]	12	India	Ahmedabad	2020 Mar - Dec, 2021 Apr - May
RAVANI, SA[134]	19	India	Ahmedabad	2020 Sep - 2021 Mar
MOORTHY, A[135]	18	India	Bangalore	2020 May - Dec
NEHARA HR[136]	5	India	Bikaner	2020 Nov - Dec
SURESH, A[137]	37	India	Dharwad	2020 Jun - 2021 May
DUBEY, S[138]	55	India	East	2021 Apr - Jun
SAIDHA, PK[139]	6	India	Gurgaon	2020 - 2021
SHARMA, S[140]	23	India	Jaipur	2020 Aug - Dec
ARJUN, R[141]	10	India	Kochi	2020 - 2021
MAHARASHTRA NEWS[142]	1,500	India	Maharashtra	2021 May 20

DAVE, TV[143]	58	India	Multicenter	2020 - 2021
SEN, M[144]	2,826	India	Multicenter	2020 Jan 1 - 2021 May 16
RAUT, A[145]	14,872	India	Multicenter	2020 - 2021 May 28
SEN, M[146]	6	India	Mumbai	2020 Aug 1 - Dec 15
PATEL, A[147]	187	India	Multicenter	2020 Sep - Dec
GUPTA, R[148]	115	India	Multicenter	2020 - 2021
RAMASWAMI, A[149]	70	India	New Delhi	2021 May 6 - Jun 1
ARORA, R[150]	65	India	New Delhi	2021 Mar - Jun 5
SINGH, Y[151]	13	India	New Delhi	2020 Nov - 2021 Jan
SARKAR, S[152]	10	India	Puducherry	2020 - 2021
JOSHI, S[153]	178	India	Pune	2020 - 2021
MISHRA, Y[154]	32	India	Pune	2021 Apr 12 - May 31
METHA, R[155]	215	India	Raipur	2021 May 1 - July 15
PIPPAL, SK[156]	80	India	Sagar	2021 May - Aug
NELWAN, EJ[157]	1	Indonesia	Jakarta	2021
AVATEF, FM[158]	12	Iran	Kermanshah	2021
ZARRINFAR, H & FATA, A[114]	1	Iran	Mashhad	2020
PAKDEL, F[159]	15	Iran	Tehran, Multicenter	2020 Apr - Sept
KARIMI-GALOUGAHI, M[160]	1	Iran	Tehran	2020
TABARSI, P[161]	1	Iran	Tehran	2020 - 2021
VEISI, A[162]	2	Iran	Tehran	2021
MOHAMMADI, F[163]	1	Iran	Qazvin	2021
OSTOVAN, VR[164]	1	Iran	Shiraz	2020
SALTINI, P[56]	1	Italy	Milan	2021
PASERO, D[165]	1	Italy	Sassari	2020 Mar
ALOBAID, K[114]	1	Kuwait	Kuwait City	2020
KANJ, S[114]	1	Lebanon	Beirut	2020
BONIFAZ, A & ARAIZA, J[114]	3	Mexico	Mexico City	2020
WAIZEL-HAIAT, S[166]	1	Mexico	Mexico City	2020
GUZMÁN-CASTRO, S[167]	6	Mexico	Morelia	2020 May - 2021 May
SHRESTHA, O[168]	1	Nepal	Biratnagar	2021
KUMAR GUPTA, S[169]	1	Nepal	Kathmandu	2021
BUIL, JB[170]	1	Netherlands	Amsterdam	2020 - 2021
BUIL, JB[170]	1	Netherlands	Breda	2020 - 2021
BUIL, JB[170]	1	Netherlands	Ede	2020 - 2021
BUIL, JB[170]	1	Netherlands	Leiden	2020 - 2021
MOBEEN, H[171]	1	Pakistan	Islamabad	2021
NASIR, N[172]	10	Pakistan	Karachi	2020 Jul - 2021 May
ALAMIN, MA[173]	1	Qatar	Doha	2021
KLIMKO, N[114]	4	Russia	Saint Petersburg	2020
ARANA, C[174]	2	Spain	Barcelona	2020
LAI, CC[175]	1	Taiwan	Tainan City	2021
MALEK, I[176]	1	Tunisia	Tunis	2021

DEMIROĞU, YZ[177]	2	Turkey	Adana	2021
BAYRAM, N[178]	11	Turkey	Kayseri	2020 Mar - Dec
SARGIN, F[179]	1	Turkey	Pamukkale	2020
DILEK, A[180]	1	Turkey	Samsun	2021
HANLEY, B[181]	1	United Kingdom	London	2020 March 1 - April 30
KRISHNA, V[182]	1	United Kingdom	London	2020 Apr
PLACIK, D[183]	1	United States	Yuma, Arizona	2020
JOHNSON, A[184]	1	United States	Riverside, California	2021
DALLALZADEH, LO[185]	2	United States	San Diego, California	2020
MEKONNEN, Z[186]	1	United States	San Francisco, California	2020
KANWAR, A[187]	1	United States	Lewes, Delaware	2020
ALEKSEYEV, K[188]	1	United States	Dover, Delaware	2020
WERTHMAN-EHRENREICH, A[189]	1	United States	Buffalo, New York	2020
KHATRI, A[190]	2	United States	Manhasset, New York	2020
ELHAMAMSY, S[191]	3	United States	Providence, Rhode Island	2020 - 2021
KHAN, N[192]	1	United States	San Antonio, Texas	2020
SOUQUETT GIL, M[193]	1	Venezuela	Merida	2021
SOUQUETT GIL, M[193]	3	Venezuela	Valencia	2021

8

9

c. CAC

REFERENCE	NUMBER OF CASES	COMMENT	COUNTRY	CITY	TIME PERIOD
BENEDETT, MF[194]	1	CAC	Argentina	Buenos Aires	2022
SEITZ, T[195]	1	CAC	Austria	Vienna	2020
SAEED, NK[196]	30	CAC	Bahrain	Manama	2020 Feb - Oct
DE ALMEIDA, JN[197,198]	3 (+ 9 colonizations)	*C. auris*	Brazil	Salvador	2020 Dec 7 - 30
SILVA, DL[199]	2	CAC	Brazil	Belo Horizonte	2020 May - Nov
RICHE, CVW[200]	11	CAC	Brazil	Porto Alegre	2020
NUCCI, M[201]	9	CAC	Brazil	Rio de Janeiro	2020 Jan - Feb
MARTINS, AC[14]	4	CAC	Brazil	São Paulo	2020 Feb - Dec
ZHANG, J[202]	2	CAC	China	Hangzhou	2020 Feb 12 - Mar 24
ZHU, X[18]	2	CAC	China	Nanjing	2020 Jan 22 - Feb 2
CHEN, N[20]	4	CAC	China	Wuhan	2020 Jan 1 - Jan 20
SANG, L[203]	6	CAC	China	Wuhan	2020 Jan 18 - Apr 26
RODRIGUEZ, JY[204]	6 (+ 2 colonizations)	*C. auris*	Colombia	Northern Region	2020 Jun - Sept
RODRIGUEZ, JY[204]	13	CAC	Colombia	Northern region	2020 Jun - Sep
SOLANO LEIVA, I[205]	2	*C. auris*	El Salvador	San Salvador	2020 Feb
RAMADAN, HK[206]	5	CAC	Egypt	Assiut	2020 May 3 - Jun 30
BRETAGNE, S[207]	75	CAC	France	national multicentre	2020 - 2021
BUETTI, N[208]	4	CAC	France	Paris	2020 Jan 29 - Oct 3
WIESE-POSSELT, M[209]	1 (+ 1 colonization)	*C. auris*	Germany	Berlin	2021 Jan - Mar
SPILIOPOULOU, A[210]	1	CAC	Greece	Patras	2021
PAHO REPORT[211]	2	*C. auris*	Guatemala	UNK	2020 Jun - Sep
SZABO, BG[212]	7	CAC	Hungary	Budapest	2020 Mar - Jun
CHOWDHARY, A[213]	10	*C. auris*	India	New Delhi	2020 Apr - Jul
RAJNI, E[214]	14	*C. auris*	India	Rajasthan	2020 Aug - 2021 Jan
AGARWAL, M[215]	1	CAC (eye)	India	Bengaluru	
SURESH, A[137]	1	CAC	India	Dharwad	2020 Jun - 2021 May
NIYAS, VKM[216]	1	C. auris	India	Kerala	2020 Jul 5 - 2021 Feb 28
NIYAS, VKM[216]	3	CAC	India	Kerala	2020 Jul 5 - 2021 Feb 28
CHOWDHARY, A[213]	5	CAC	India	New Delhi	2020 Apr - Jul
SHROFF, D[217]	4	CAC	India	New Delhi	2020 May 2021 Jan
BHAGALI, R[218]	1	CAC	India	Pune	

RAJNI, E[214]	14	C. auris	India	Rajasthan	2020 Aug - 2021 Jan
RAJNI, E[214]	19	CAC	India	Rajasthan	2020 Aug - 2021 Jan
GOYAL, M[219]	1	CAC	India	Telangana	
SARI, AP[220]	1	CAC	Indonesia	Jakarta	
ARASTEHFAR, A[221]	6	CAC	Iran	Mashhad	2020 Nov - 2021 Jan
DAVOODI, L[222]	1	CAC	Iran	Sari	2020 Jul
		CAC	Iran		
HEBERT, J[223]	1	CAC	Ireland	Dublin	
BRIKMAN, S[224]	3	CAC	Israel	Afula	2020 Jun 15 - Sep 20
AYALON, O[225]	11	CAC	Israel	Jerusalem	2020 Sep 1 - Nov 30 & 2021 Dec 1 - Mar 31
MAGNASCO, L[226]	4 (+ 2 colonizations)	*C. auris*	Italy	Genoa	2020 Feb 28 - May 31
DI PILATO, V[227]	UNK (1 – 5)	*C. auris*	Italy	Genoa	2019 Jul – 2020 May
SIGNORINI, L[54]	5	CAC	Italy	Brescia	2020 Feb 21 - May 6
CULTRERA, R[229]	6	CAC	Italy	Ferrara	2020 Feb 22 - Apr 30
ANTINORI, S[230]	3	CAC	Italy	Milan	2020 Mar 10 - 18
MASTRANGELO, A[231]	21	CAC	Italy	Milan	2020 Feb 15 - Jun 30
POSTERARO, B[232]	8	CAC	Italy	Rome	2020 Mar 1 - May 31
GIACOBBE, DR[233]	3	CAC	Italy	San Martino	2020 Feb 20 - Apr 10
YAMAMOTO, K[234]	1	CAC	Japan	Okayama	
BABA, H[235]	1	CAC	Japan	Sendai	
ALLAW, F[236]	4 (+ 3 colonizations)	*C. auris*	Lebanon	Beirut	2020 Oct 7 - Dec 30
AWADA, B[237]	1	CAC	Lebanon	Beirut	
VILLANUEVA-LOZANO, H[238]	12	*C. auris*	Mexico	Nuevo Leon	2020 Aug
AL-HATMI, AMS[239]	5	CAC	Oman	Muscat	2020
MOIN, S[240]	4	*C. auris*	Pakistan	Karachi	2020 Apr - Dec
MOIN, S[241]	22	CAC	Pakistan	Karachi	2020 Apr - Dec
PAHO REPORT[211]	(108 isolates)	*C. auris*	Panama	national	2020 Jun - Sept
PAHO REPORT[211]	1	*C. auris*	Peru	Lima	2020 Jun - Sep
MIRANDA, MA[242]	1	CAC	Portugal	Cascais	
OMRANI, AS[243]	7	*C. auris*	Qatar	Doha	March 1, 2020 and April 30, 2021
GORAVEY, W[244]	1	*C. auris*	Qatar	Doha	0
OMRANI, AS[243]	77	CAC	Qatar	Doha	2020 Mar 1 - 2021 Apr 30

KLIMKO, N, KOZLOVA O[245]	60	CAC	Russia	St. Petersburg	2020 Mar – 2022 Mar
AL ARGAN, RJ[246]	1	CAC	Saudi Arabia	Khobar	
ALFONSO-SANCHEZ, JL[247]	14	*C. auris*	Spain	Valencia	2020 Feb - 2021 Feb
SEGRELLES-CALVO, G[249]	3	CAC	Spain	Madrid	2020 Feb 1 - Apr 30
GOROSPE-SARASÚA, L[250]	1	CAC	Spain	Madrid	
MORENO-GÓMEZ, LM[251]	1	CAC	Spain	Madrid	
KALUARACHCHI, S[252]	1	CAC (eye)	Sri Lanka	Colombo	
KÖMEÇ, S[253]	1 (+ 2 non-COVID-19)	*C. auris*	Turkey	Istanbul	2020 Nov - 2021 Jan
BÖLÜKBAŞI, Y[254]	1	*C. auris*	Turkey	Istanbul	
KAYAASLAN, B[255]	105	CAC	Turkey	Ankara	2020 Mar 1 - 2021 Mar 1
COŞKUN, AS[256]	15	CAC	Turkey	Antalya	2020 Mar 13 - 2021 Jan 02
GÖRKEM, A[257]	1	CAC	Turkey	Kayseri	
SENOK, A[258]	1	*C. auris*	United Arab Emirates	Dubai	2020 Feb 1 - Jul 31
WHITE, L[259]	7	CAC	United Kingdom	Cardiff	2020 - 2021
CLOUGH, N[260]	5	CAC	United Kingdom	London	2020 Feb - Apr
HUGHES, S[104]	3	CAC	United Kingdom	London	2020 Feb 20 - Apr 30
HANSON, BM[228]	12	*C. auris*	United States	Miami	2020 Summer
JEFFERSON, E[261]	1	*C. auris*	United States	San Diego	2020 Mar
PRESTEL, C[262]**/HANSON, BM**[228]	9 (+ 25 colonizations)/12	*C. auris*	United States	Miami	2020 Jun - Sept
KORDALEWSKA, M[263]	11	CAC	United States	Nutley	2020 Apr - May
BISHBURG, E[264]	8	CAC	United States	New Jersey	2020
MIRCHIN, R[265]	1	CAC	United States	New York	
NORI, P[266]	8	CAC	United States	New York	2020 Mar 1 - Apr 18
STURM, LK[267]	21	CAC	United States	Saint Louis	2020 Mar 1 - 2021 Apr 30
ALATABY, H[268]	1	CAC	United States	Staten Island	
MACAULEY, P[269]	12	CAC	United States	Valhalla	2019 Dec - 2020 Oct
SEAGLE, EE[270]	251	CAC	United States	National	2020 Apr - Aug

References

1. Fernandez NB, Caceres DH, Beer KD, et al. Ventilator-associated pneumonia involving Aspergillus flavus in a patient with coronavirus disease 2019 (COVID-19) from Argentina. *Med Mycol Case Rep* 2021; **31**: 19-23.
2. Benedetti MF, Alava KH, Sagardia J, et al. COVID-19 associated pulmonary aspergillosis in ICU patients: Report of five cases from Argentina. *Med Mycol Case Rep* 2021; **31**: 24-8.
3. Sasoni N, Rodriguez Muller M, Posse G, Gonzalez J, Leonardelli F, Garcia-Effron G. SARS-CoV-2 and Aspergillus section Fumigati coinfection in an immunocompetent patient treated with corticosteroids. *Rev Iberoam Micol* 2021; **38**(1): 16-8.

4. Sharma A, Hofmeyr A, Bansal A, et al. COVID-19 associated pulmonary aspergillosis (CAPA): An Australian case report. *Med Mycol Case Rep* 2021; **31**: 6-10.
5. Prattes J, Wauters J, Giacobbe DR, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients- a multinational observational study by the European Confederation of Medical Mycology. *Clin Microbiol Infect* 2021.
6. Prattes J, Valentin T, Hoenigl M, Talakic E, Reisinger AC, Eller P. Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - A case report. *Med Mycol Case Rep* 2021; **31**: 2-5.
7. Van Ackerbroeck S, Rutsaert L, Roelant E, Dillen K, Wauters J, Van Regenmortel N. Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis/aspergillus tracheobronchitis. *Crit Care* 2021; **25**(1): 298.
8. Rutsaert L, Steinfort N, Van Hunsel T, et al. COVID-19-associated invasive pulmonary aspergillosis. *Ann Intensive Care* 2020; **10**(1): 71.
9. Janssen NAF, Nyga R, Vanderbeke L, et al. Multinational Observational Cohort Study of COVID-19-Associated Pulmonary Aspergillosis(1). *Emerg Infect Dis* 2021; **27**(11): 2892-8.
10. Sarrazyn C, Dhaese S, Demey B, Vandecasteele S, Reynders M, Van Praet JT. Incidence, risk factors, timing, and outcome of influenza versus COVID-19-associated putative invasive aspergillosis. *Infect Control Hosp Epidemiol* 2021; **42**(9): 1149-50.
11. Santana MF, Pivoto G, Alexandre MAA, et al. Confirmed Invasive Pulmonary Aspergillosis and COVID-19: the value of postmortem findings to support antemortem management. *Rev Soc Bras Med Trop* 2020; **53**: e20200401.
12. Farias ME, Santana MF, Ferreira L, et al. COVID-19-Associated Pulmonary Aspergillosis in a Series of Complete Autopsies from the Brazilian Amazon. *Am J Trop Med Hyg* 2022; **106**(2): 571-3.
13. de Almeida JN, Jr., Doi AM, Watanabe MJL, et al. COVID-19-associated aspergillosis in a Brazilian referral centre: Diagnosis, risk factors and outcomes. *Mycoses* 2022.
14. Martins AC, Psaltikidis EM, de Lima TC, et al. COVID-19 and invasive fungal coinfections: A case series at a Brazilian referral hospital. *J Mycol Med* 2021; **31**(4): 101175.
15. Rabagliati R, Rodriguez N, Nunez C, Huete A, Bravo S, Garcia P. COVID-19-Associated Mold Infection in Critically Ill Patients, Chile. *Emerg Infect Dis* 2021; **27**(5): 1454-6.
16. Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. *Crit Care* 2020; **24**(1): 299.
17. Fu Y, Yang Q, Xu M, et al. Secondary Bacterial Infections in Critical Ill Patients With Coronavirus Disease 2019. *Open Forum Infect Dis* 2020; **7**(6): ofaa220.
18. Zhu X, Ge Y, Wu T, et al. Co-infection with respiratory pathogens among COVID-2019 cases. *Virus Res* 2020; **285**: 198005.
19. Jiang Z, Chen S, Zhu Q, Xiao Y, Qu J. COVID-19-associated pulmonary aspergillosis in a tertiary care center in Shenzhen City. *J Infect Public Health* 2022; **15**(2): 222-7.
20. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 2020; **395**(10223): 507-13.
21. Xu J, Yang X, Lv Z, et al. Risk Factors for Invasive Aspergillosis in Patients Admitted to the Intensive Care Unit With Coronavirus Disease 2019: A Multicenter Retrospective Study. *Front Med (Lausanne)* 2021; **8**: 753659.
22. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med* 2020; **8**(5): 475-81.
23. Haglund A, Christensen S, Kristensen L, Gertsen JB, Buus L, Lausch KR. Invasive pulmonary aspergillosis and hyperthermia in an immunocompetent patient with COVID-19. *Med Mycol Case Rep* 2021; **31**: 29-31.
24. Helleberg M, Steensen M, Arendrup MC. Invasive aspergillosis in patients with severe COVID-19 pneumonia. *Clin Microbiol Infect* 2021; **27**(1): 147-8.
25. Ismaiel WF, Abdelazim MH, Eldsoky I, et al. The impact of COVID-19 outbreak on the incidence of acute invasive fungal rhinosinusitis. *Am J Otolaryngol* 2021; **42**(6): 103080.

26. Rouze A, Lemaitre E, Martin-Loeches I, et al. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study. *Crit Care* 2022; **26**(1): 11.
27. Razazi K, Arrestier R, Haudebourg AF, et al. Risks of ventilator-associated pneumonia and invasive pulmonary aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease. *Crit Care* 2020; **24**(1): 699.
28. Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series. *Lancet Infect Dis* 2020; **20**(6): 697-706.
29. Gouzien L, Cocherie T, Eloy O, et al. Invasive Aspergillosis associated with Covid-19: A word of caution. *Infect Dis Now* 2021; **51**(4): 383-6.
30. Dupont D, Menotti J, Turc J, et al. Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19). *Med Mycol* 2021; **59**(1): 110-4.
31. Fekkar A, Lampros A, Mayaux J, et al. Occurrence of Invasive Pulmonary Fungal Infections in Patients with Severe COVID-19 Admitted to the ICU. *Am J Respir Crit Care Med* 2021; **203**(3): 307-17.
32. Ghelfenstein-Ferreira T, Saade A, Alanio A, et al. Recovery of a triazole-resistant Aspergillus fumigatus in respiratory specimen of COVID-19 patient in ICU - A case report. *Med Mycol Case Rep* 2021; **31**: 15-8.
33. Delliere S, Dudoignon E, Fodil S, et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. *Clin Microbiol Infect* 2020.
34. Blaize M, Mayaux J, Nabet C, et al. Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. *Emerg Infect Dis* 2020; **26**(7): 1636-7.
35. Gangneux JP, Reizine F, Guegan H, et al. Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience. *J Fungi (Basel)* 2020; **6**(3).
36. Reizine F, Pinceaux K, Lederlin M, et al. Influenza- and COVID-19-Associated Pulmonary Aspergillosis: Are the Pictures Different? *J Fungi (Basel)* 2021; **7**(5).
37. Schein F, Munoz-Pons H, Mahinc C, Grange R, Cathebras P, Flori P. Fatal aspergillosis complicating severe SARS-CoV-2 infection: A case report. *J Mycol Med* 2020; **30**(4): 101039.
38. Versyck M, Zarrougui W, Lambiotte F, Elbeki N, Saint-Leger P. Invasive pulmonary aspergillosis in COVID-19 critically ill patients: Results of a French monocentric cohort. *J Mycol Med* 2021; **31**(2): 101122.
39. Ichai P, Saliba F, Baune P, Daoud A, Coilly A, Samuel D. Impact of negative air pressure in ICU rooms on the risk of pulmonary aspergillosis in COVID-19 patients. *Crit Care* 2020; **24**(1): 538.
40. Leistner R, Schroeter L, Adam T, et al. Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients. *Crit Care* 2022; **26**(1): 30.
41. Koehler P, Cornely OA, Böttiger BW, et al. COVID-19 Associated Pulmonary Aspergillosis. *Mycoses* 2020.
42. Kirchhoff L, Braun LM, Schmidt D, et al. COVID-19-associated pulmonary aspergillosis in ICU patients in a German reference centre: Phenotypic and molecular characterisation of Aspergillus fumigatus isolates. *Mycoses* 2022.
43. Rothe K, Feihl S, Schneider J, et al. Rates of bacterial co-infections and antimicrobial use in COVID-19 patients: a retrospective cohort study in light of antibiotic stewardship. *Eur J Clin Microbiol Infect Dis* 2021; **40**(4): 859-69.
44. Lahmer T, Rasch S, Spinner C, Geisler F, Schmid RM, Huber W. Invasive pulmonary aspergillosis in severe coronavirus disease 2019 pneumonia. *Clin Microbiol Infect* 2020; **26**(10): 1428-9.
45. Paramythiotou E, Dimopoulos G, Koliakos N, et al. Epidemiology and Incidence of COVID-19-Associated Pulmonary Aspergillosis (CAPA) in a Greek Tertiary Care Academic Reference Hospital. *Infect Dis Ther* 2021; **10**(3): 1779-92.
46. Nasri E, Shoaei P, Vakili B, et al. Fatal Invasive Pulmonary Aspergillosis in COVID-19 Patient with Acute Myeloid Leukemia in Iran. *Mycopathologia* 2020; **185**(6): 1077-84.

47. Hakamifard A, Hashemi M, Fakhim H, Aboutalebian S, Hajiahmadi S, Mohammadi R. Fatal disseminated aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus ochraceus. *J Mycol Med* 2021; **31**(2): 101124.
48. Ghazanfari M, Arastehfar A, Davoodi L, et al. Pervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients. *Front Med (Lausanne)* 2021; **8**: 649675.
49. Salehi M, Khajavirad N, Seifi A, et al. Proven Aspergillus flavus pulmonary aspergillosis in a COVID-19 patient: A case report and review of the literature. *Mycoses* 2021; **64**(8): 809-16.
50. Abolghasemi S, Hakamifard A, Sharifynia S, Pourabdollah Toutkaboni M, Azhdari Tehrani H. Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVID-19 due to Aspergillus terreus: A case study. *Clin Case Rep* 2021; **9**(4): 2414-8.
51. Kakamad FH, Mahmood SO, Rahim HM, et al. Post covid-19 invasive pulmonary Aspergillosis: A case report. *Int J Surg Case Rep* 2021; **82**: 105865.
52. Mohamed A, Hassan T, Trzos-Grzybowska M, et al. Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2 co-infection: A lethal combination. *Med Mycol Case Rep* 2021; **31**: 11-4.
53. Bartoletti M, Pascale R, Cricca M, et al. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study. *Clin Infect Dis* 2020.
54. Signorini L, Moioli G, Calza S, et al. Epidemiological and Clinical Characterization of Superinfections in Critically Ill Coronavirus Disease 2019 Patients. *Crit Care Explor* 2021; **3**(6): e0430.
55. Trovato L, Calvo M, Migliorisi G, Astuto M, Oliveri F, Oliveri S. Fatal VAP-related pulmonary aspergillosis by Aspergillus niger in a positive COVID-19 patient. *Respir Med Case Rep* 2021; **32**: 101367.
56. Saltini P, Palomba E, Castelli V, et al. Mucormycosis in CAPA, a Possible Fungal Super-Infection. *J Fungi (Basel)* 2021; **7**(9).
57. Ripa M, Galli L, Poli A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. *Clin Microbiol Infect* 2021; **27**(3): 451-7.
58. Antinori S, Rech R, Galimberti L, et al. Invasive pulmonary aspergillosis complicating SARS-CoV-2 pneumonia: A diagnostic challenge. *Travel Med Infect Dis* 2020; **38**: 101752.
59. Fortarezza F, Boscolo A, Pezzuto F, et al. Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure. *Mycoses* 2021; **64**(10): 1223-9.
60. Falcone M, Tiseo G, Giordano C, et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. *J Antimicrob Chemother* 2021; **76**(4): 1078-84.
61. Oliva A, Ceccarelli G, Borrazzo C, et al. Comparison of clinical features and outcomes in COVID-19 and influenza pneumonia patients requiring intensive care unit admission. *Infection* 2021; **49**(5): 965-75.
62. Bruno G, Fabrizio C, Buccoliero GB. COVID-19-associated pulmonary aspergillosis: adding insult to injury. *Lancet Microbe* 2020; **1**(3): e106.
63. Baratella E, Roman-Pognuz E, Zerbato V, et al. Potential links between COVID-19-associated pulmonary aspergillosis and bronchiectasis as detected by high resolution computed tomography. *Front Biosci (Landmark Ed)* 2021; **26**(12): 1607-12.
64. Berlot G, Tomasini A, Bussani R. Diffuse aspergillosis in a patient with SARS-CoV-2 pneumonia. *Intensive Care Med* 2021.
65. Iwanaga Y, Kawanami T, Yamasaki K, et al. A fatal case of COVID-19-associated invasive pulmonary aspergillosis. *J Infect Chemother* 2021; **27**(7): 1102-7.
66. Takazono T, Mukae H, Izumikawa K, Hasegawa N, Yokoyama A. COVID-19 associated pulmonary aspergillosis: a nationwide survey by the Japanese Respiratory Society. *ERJ Open Res* 2021; **7**(4).
67. Imoto W, Himura H, Matsuo K, et al. COVID-19-associated pulmonary aspergillosis in a Japanese man: A case report. *J Infect Chemother* 2021; **27**(6): 911-4.
68. Alobaid K, Yousuf B, Al-Qattan E, Muqeem Z, Al-Subaie N. Pulmonary aspergillosis in two COVID-19 patients from Kuwait. *Access Microbiol* 2021; **3**(3): 000201.

69. Velez Pintado M, Camiro-Zuniga A, Aguilar Soto M, et al. COVID-19-associated invasive pulmonary aspergillosis in a tertiary care center in Mexico City. *Med Mycol* 2021; **59**(8): 828-33.
70. Roman-Montes CM, Martinez-Gamboa A, Diaz-Lomeli P, et al. Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis. *Mycoses* 2021; **64**(4): 364-71.
71. van Someren Greve F, du Long R, Talwar R, Beurskens CJP, Voerman HJ, van Dijk K. Proven Fatal Invasive Aspergillosis in a Patient with COVID-19 and Staphylococcus aureus Pneumonia. *J Fungi (Basel)* 2021; **7**(3).
72. Van Biesen S, Kwa D, Bosman RJ, Juffermans NP. Detection of Invasive Pulmonary Aspergillosis in COVID-19 with Non-directed Bronchoalveolar Lavage. *Am J Respir Crit Care Med* 2020.
73. van Grootveld R, van Paassen J, de Boer MGJ, et al. Systematic screening for COVID-19 associated invasive aspergillosis in ICU patients by culture and PCR on tracheal aspirate. *Mycoses* 2021; **64**(6): 641-50.
74. van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated Pulmonary Aspergillosis. *Am J Respir Crit Care Med* 2020; **202**(1): 132-5.
75. Meijer EFJ, Dofferhoff ASM, Hoiting O, Meis JF. COVID-19-associated pulmonary aspergillosis: a prospective single-center dual case series. *Mycoses* 2021; **64**(4): 457-64.
76. Yusuf E, Vonk A, van den Akker JPC, et al. Frequency of Positive Aspergillus Tests in COVID-19 Patients in Comparison to Other Patients with Pulmonary Infections Admitted to the Intensive Care Unit. *J Clin Microbiol* 2021; **59**(3).
77. Iqbal A, Ramzan M, Akhtar A, Ahtesham A, Aslam S, Khalid J. COVID-Associated Pulmonary Aspergillosis and Its Related Outcomes: A Single-Center Prospective Observational Study. *Cureus* 2021; **13**(8): e16982.
78. Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. *Mycoses* 2020; **63**(8): 766-70.
79. Wachnicka-Truty R, Curyllo B, Wojtowicz D, et al. Life-threatening COVID-19 and aspergillosis co-infection in a heart transplant recipient: A cardiologist's nightmare. *Cardiol J* 2022.
80. Ranhel D, Ribeiro A, Batista J, et al. COVID-19-Associated Invasive Pulmonary Aspergillosis in the Intensive Care Unit: A Case Series in a Portuguese Hospital. *J Fungi (Basel)* 2021; **7**(10).
81. Abdalla S, Almaslamani MA, Hashim SM, Ibrahim AS, Omrani AS. Fatal Coronavirus Disease 2019-associated Pulmonary Aspergillosis; A Report of Two Cases and Review of the Literature. *IDCases* 2020; **22**: e00935.
82. Toc DA, Costache C, Botan A, et al. Mixed Etiology COVID-19 Associated Pulmonary Aspergillosis (CAPA)-A Case Report and Brief Review of the Literature. *J Fungi (Basel)* 2021; **7**(10).
83. Klimko N. CAPA in Russia, site unknown. In: Danila Seidel F, editor.; 2021.
84. Shadrivova O, Gusev D, Vashukova M, et al. COVID-19-Associated Pulmonary Aspergillosis in Russia. *J Fungi (Basel)* 2021; **7**(12).
85. Albasata H, Alamri MM, Almuhaidb SA, Aljebreen AM, Almaghrabia RS. Case Report: Diagnostic challenge of COVID-19 associated pulmonary aspergillosis (CAPA). *F1000 Research* 2021; **10**(58): 1-12.
86. Marr KA, Platt A, Tornheim JA, et al. Aspergillosis Complicating Severe Coronavirus Disease. *Emerg Infect Dis* 2021; **27**(1).
87. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect* 2021; **27**(1): 83-8.
88. Segrelles-Calvo G, Araujo GRS, Llopis-Pastor E, et al. Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia. *Mycoses* 2021; **64**(2): 144-51.
89. Machado M, Valerio M, Alvarez-Uria A, et al. Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity. *Mycoses* 2021; **64**(2): 132-43.

90. Falces-Romero I, Ruiz-Bastian M, Diaz-Pollan B, Maseda E, Garcia-Rodriguez J, Group SA-C-W. Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish Tertiary Care Hospital. *Mycoses* 2020.
91. Bardi T, Pintado V, Gomez-Rojo M, et al. Nosocomial infections associated to COVID-19 in the intensive care unit: clinical characteristics and outcome. *Eur J Clin Microbiol Infect Dis* 2021; **40**(3): 495-502.
92. Trujillo H, Fernandez-Ruiz M, Gutierrez E, et al. Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient. *Transpl Infect Dis* 2021; **23**(2): e13501.
93. Calderon-Parra J, Mills-Sanchez P, Moreno-Torres V, et al. COVID-19-associated pulmonary aspergillosis (CAPA): Risk factors and development of a predictive score for critically ill COVID-19 patients. *Mycoses* 2022.
94. Garcia Clemente M, Hermida Valverde T, Leizaola-Irigoyen O, et al. [Can SARS-CoV-2 be a Risk Factor for Pulmonary Aspergillosis?]. *Arch Bronconeumol* 2021; **57**: 72-3.
95. Marta GC, Lorena FE, Laura MV, et al. COVID-19-Associated Pulmonary Aspergillosis in a Tertiary Hospital. *J Fungi (Basel)* 2022; **8**(2).
96. Martin CS, Martine EM, Pellicer RG, Ibanez RA, Gonzalez EM, Pitarch JVL. [Invasive Pulmonary Aspergillosis in Patients with Acute Respiratory Syndrome by Covid-19.]. *Rev Esp Anestesiol Reanim (Engl Ed)* 2021.
97. Nebreda-Mayoral T, Miguel-Gomez MA, March-Rossello GA, et al. Bacterial/fungal infection in hospitalized patients with COVID-19 in a tertiary hospital in the Community of Castilla y Leon, Spain. *Enferm Infecc Microbiol Clin (Engl Ed)* 2020.
98. Sogaard KK, Baettig V, Osthoff M, et al. Community-acquired and hospital-acquired respiratory tract infection and bloodstream infection in patients hospitalized with COVID-19 pneumonia. *J Intensive Care* 2021; **9**(1): 10.
99. Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients. *Clin Microbiol Infect* 2020.
100. Lu DE, Hung SH, Su YS, Lee WS. Analysis of Fungal and Bacterial Co-Infections in Mortality Cases among Hospitalized Patients with COVID-19 in Taipei, Taiwan. *J Fungi (Basel)* 2022; **8**(1).
101. Chauvet P, Mallat J, Arumadura C, et al. Risk Factors for Invasive Pulmonary Aspergillosis in Critically Ill Patients With Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome. *Crit Care Explor* 2020; **2**(11): e0244.
102. Maes M, Higginson E, Pereira-Dias J, et al. Correction to: Ventilator-associated pneumonia in critically ill patients with COVID-19. *Crit Care* 2021; **25**(1): 130.
103. White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. *Clin Infect Dis* 2020.
104. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. *Clin Microbiol Infect* 2020; **26**(10): 1395-9.
105. Borman AM, Palmer MD, Fraser M, et al. COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory. *J Clin Microbiol* 2020; **59**(1).
106. Witting C, Quaggin-Smith J, Mylvaganam R, Peigh G, Angarone M, Flaherty JD. Invasive pulmonary aspergillosis after treatment with tocilizumab in a patient with COVID-19 ARDS: a case report. *Diagn Microbiol Infect Dis* 2021; **99**(4): 115272.
107. Permpalung N, Chiang TP, Massie AB, et al. COVID-19 Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients. *Clin Infect Dis* 2021.
108. Wasylyshyn AI, Wasylyshyn GR, Linder KA, Miceli MH. COVID-19-Associated Pulmonary Aspergillosis at an Academic Medical Center in the Midwestern United States. *Mycopathologia* 2021; **186**(4): 499-505.
109. Mitaka H, Perlman DC, Javaid W, Salomon N. Putative invasive pulmonary aspergillosis in critically ill patients with COVID-19: An observational study from New York City. *Mycoses* 2020; **63**(12): 1368-72.
110. Patti RK, Dalsania NR, Somal N, et al. Subacute Aspergillosis "Fungal Balls" Complicating COVID-19. *J Investig Med High Impact Case Rep* 2020; **8**: 2324709620966475.

111. Nasrullah A, Javed A, Malik K. Coronavirus Disease-Associated Pulmonary Aspergillosis: A Devastating Complication of COVID-19. *Cureus* 2021; **13**(1): e13004.
112. Steenwyk JL, Mead ME, de Castro PA, et al. Genomic and Phenotypic Analysis of COVID-19-Associated Pulmonary Aspergillosis Isolates of Aspergillus fumigatus. *Microbiol Spectr* 2021; **9**(1): e0001021.
113. Zurl C, Hoenigl M, Schulz E, et al. Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy. *J Fungi (Basel)* 2021; **7**(2).
114. Hoenigl MS, D; Carvalho, Ag; Rudramurthy, SM; Arastehfar, A; Gangneux, JP; Nasir, N; Bonifaz, A; Araiza, J; Klimko, N; Serris, A; Lagrou, K; Meis, JF; Cornely, OA; Perfect, JR; White, PL; Chakrabarti, A; and Group, ECMM and ISHAM Collaborators. The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries. *Available at SSRN: https://ssrncom/abstract=3844587 or http://dxdoiorg/102139/ssrn3844587* 2021.
115. Pauli MA, Pereira LM, Monteiro ML, de Camargo AR, Rabelo GD. Painful palatal lesion in a patient with COVID-19. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2021; **131**(6): 620-5.
116. Bonates P, Joao GAP, Cruz KS, et al. Fatal rhino-orbito-cerebral mucormycosis infection associated with diabetic ketoacidosis post-COVID-19. *Rev Soc Bras Med Trop* 2021; **54**: e03582021.
117. Monte Junior ESD, Santos M, Ribeiro IB, et al. Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report. *Clin Endosc* 2020; **53**(6): 746-9.
118. Venugopal A, Marya A. Palatal mucormycosis in a patient with SARS-CoV-2 infection. *CMAJ* 2021; **193**(32): E1254.
119. He Y, Li W, Wang Z, Chen H, Tian L, Liu D. Nosocomial infection among patients with COVID-19: A retrospective data analysis of 918 cases from a single center in Wuhan, China. *Infect Control Hosp Epidemiol* 2020; **41**(8): 982-3.
120. Crone CG, Helweg-Larsen J, Steensen M, Arendrup MC, Helleberg M. Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap. *J Mycol Med* 2021; **32**(1): 101228.
121. Alfishawy M, Elbendary A, Younes A, et al. Diabetes mellitus and Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): A wake-up call from Egypt. *Diabetes Metab Syndr* 2021; **15**(5): 102195.
122. Saad RH, Mobarak FA. The diversity and outcome of post-covid mucormycosis: A case report. *Int J Surg Case Rep* 2021; **88**: 106522.
123. Roushdy T, Hamid E. A case series of post COVID-19 mucormycosis-a neurological prospective. *Egypt J Neurol Psychiatr Neurosurg* 2021; **57**(1): 100.
124. Fouad YA, Abdelaziz TT, Askoura A, et al. Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic. *Front Med (Lausanne)* 2021; **8**: 645270.
125. El-Kholy NA, El-Fattah AMA, Khafagy YW. Invasive Fungal Sinusitis in Post COVID-19 Patients: A New Clinical Entity. *Laryngoscope* 2021; **131**(12): 2652-8.
126. Riad A, Shabaan AA, Issa J, et al. COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors. *J Fungi (Basel)* 2021; **7**(10).
127. Bellanger AP, Navellou JC, Lepiller Q, et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. *Infect Dis Now* 2021; **51**(7): 633-5.
128. Benhadid-Brahmi Y, Hamane S, Soyer B, et al. COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature review. *J Mycol Med* 2021; **32**(1): 101231.
129. Danion F, Letscher-Bru V, Guitard J, et al. Coronavirus Disease 2019-Associated Mucormycosis in France: A Rare but Deadly Complication. *Open Forum Infect Dis* 2022; **9**(2): ofab566.
130. Seidel D, Simon M, Sprute R, et al. Results from a national survey on COVID-19 associated mucormycosis in Germany: 13 patients from six tertiary hospitals. *Mycoses* 2021.

131. Selarka L, Sharma S, Saini D, et al. Mucormycosis and COVID-19: An epidemic within a pandemic in India. *Mycoses* 2021; **64**(10): 1253-60.
132. Desai EJ, Pandya A, Upadhya I, Patel T, Banerjee S, Jain V. Epidemiology, Clinical Features and Management of Rhino Orbital Mucormycosis in Post COVID 19 Patients. *Indian J Otolaryngol Head Neck Surg* 2021: 1-5.
133. Kute VB, Meshram HS, Navadiya VV, et al. Consequences of the first and second COVID-19 wave on kidney transplant recipients at a large Indian transplant centre. *Nephrology (Carlton)* 2021.
134. Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: Mucormycosis in COVID-19 times. *Indian J Ophthalmol* 2021; **69**(6): 1563-8.
135. Moorthy A, Gaikwad R, Krishna S, et al. SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids-An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. *J Maxillofac Oral Surg* 2021: 1-8.
136. Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India. *Indian J Med Microbiol* 2021; **39**(3): 380-3.
137. Suresh A, Joshi A, Desai AK, et al. Covid-19-associated fungal osteomyelitis of jaws and sinuses: An experience-driven management protocol. *Med Mycol* 2022; **60**(2).
138. Dubey S, Mukherjee D, Sarkar P, et al. COVID-19 associated rhino-orbital-cerebral mucormycosis: An observational study from Eastern India, with special emphasis on neurological spectrum. *Diabetes Metab Syndr* 2021; **15**(5): 102267.
139. Saidha PK, Kapoor S, Das P, et al. Mucormycosis of Paranasal Sinuses of Odontogenic Origin Post COVID19 Infection: A Case Series. *Indian J Otolaryngol Head Neck Surg* 2021: 1-5.
140. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. *J Laryngol Otol* 2021; **135**(5): 442-7.
141. Arjun R, Felix V, Niyas VKM, et al. COVID-19 associated Rhino-orbital Mucormycosis: a Single Centre Experience of Ten Cases. *QJM* 2021.
142. Now T. Maharashtra facing shortage of mucormycosis medicine, 1,500 cases reported so far: Health Minister Rajesh Tope. May 20, 2021 2021. https://www.timesnownews.com/india/maharashtra-news/article/maharashtra-facing-shortage-of-mucormycosis-medicine-1500-cases-reported-so-far-health-minister-rajesh-tope/759217 (accessed 16.11.2021 2021).
143. Dave TV, Gopinathan Nair A, Hegde R, et al. Clinical Presentations, Management and Outcomes of Rhino-Orbital-Cerebral Mucormycosis (ROCM) Following COVID-19: A Multi-Centric Study. *Ophthalmic Plast Reconstr Surg* 2021; **37**(5): 488-95.
144. Sen M, Honavar SG, Bansal R, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. *Indian J Ophthalmol* 2021; **69**(7): 1670-92.
145. Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? *The Lancet Respiratory Medicine* 2021.
146. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a Viral Land: A Tale of Two Pathogens. *Indian J Ophthalmol* 2021; **69**(2): 244-52.
147. Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India. *Emerg Infect Dis* 2021; **27**(9): 2349-59.
148. Gupta R, Kesavadev J, Krishnan G, et al. COVID-19 associated mucormycosis: A Descriptive Multisite Study from India. *Diabetes Metab Syndr* 2021; **15**(6): 102322.
149. Ramaswami A, Sahu AK, Kumar A, et al. COVID-19-associated mucormycosis presenting to the Emergency Department-an observational study of 70 patients. *QJM* 2021; **114**(7): 464-70.
150. Arora R, Goel R, Khanam S, et al. Rhino-Orbito-Cerebral-Mucormycosis During the COVID-19 Second Wave in 2021 - A Preliminary Report from a Single Hospital. *Clin Ophthalmol* 2021; **15**: 3505-14.
151. Singh Y, Ganesh V, Kumar S, et al. Coronavirus Disease-Associated Mucormycosis from a Tertiary Care Hospital in India: A Case Series. *Cureus* 2021; **13**(7): e16152.

152. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. *Indian J Ophthalmol* 2021; **69**(4): 1002-4.
153. Joshi S, Telang R, Tambe M, et al. Outbreak of Mucormycosis in Coronavirus Disease Patients, Pune, India. *Emerg Infect Dis* 2021; **28**(1).
154. Mishra Y, Prashar M, Sharma D, Akash, Kumar VP, Tilak T. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. *Diabetes Metab Syndr* 2021; **15**(4): 102196.
155. Mehta R, Nagarkar NM, Jindal A, et al. Multidisciplinary Management of COVID-Associated Mucormycosis Syndemic in India. *Indian J Surg* 2021: 1-9.
156. Pippal SK, Kumar D, Ukawat L. Management Challenge of Rhino-Orbito-Cerebral Mucormycosis in Covid 19 Era: A Prospective Observational Study. *Indian J Otolaryngol Head Neck Surg* 2021: 1-7.
157. Nelwan EJ, Tunjungputri RN, Wardani RS, Wahyuningsih R. Black Fungus Complicated with COVID-19 in a Man with Underlying Non-Hodgkin's Lymphoma. *Acta Med Indones* 2021; **53**(3): 349-51.
158. Avatef Fazeli M, Rezaei L, Javadirad E, et al. Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study. *Mycoses* 2021; **64**(11): 1366-77.
159. Pakdel F, Ahmadikia K, Salehi M, et al. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. *Mycoses* 2021; **64**(10): 1238-52.
160. Karimi-Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). *Int Forum Allergy Rhinol* 2021; **11**(6): 1029-30.
161. Tabarsi P, Khalili N, Pourabdollah M, et al. Case Report: Coronavirus Disease 2019-associated Rhinosinusitis Mucormycosis Caused by Rhizopus arrhizus: A Rare but Potentially Fatal Infection Occurring After Treatment with Corticosteroids. *Am J Trop Med Hyg* 2021.
162. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. *Eur J Ophthalmol* 2021: 11206721211009450.
163. Mohammadi F, Badri M, Safari S, Hemmat N. A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: a systematic review of literature and current update. *BMC Infect Dis* 2021; **21**(1): 906.
164. Ostovan VR, Rezapanah S, Behzadi Z, et al. Coronavirus disease (COVID-19) complicated by rhino-orbital-cerebral mucormycosis presenting with neurovascular thrombosis: a case report and review of literature. *J Neurovirol* 2021; **27**(4): 644-9.
165. Pasero D, Sanna S, Liperi C, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. *Infection* 2021; **49**(5): 1055-60.
166. Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A Case of Fatal Rhino-Orbital Mucormycosis Associated With New Onset Diabetic Ketoacidosis and COVID-19. *Cureus* 2021; **13**(2): e13163.
167. Guzman-Castro S, Chora-Hernandez LD, Trujillo-Alonso G, et al. COVID-19-associated mucormycosis, diabetes and steroid therapy: Experience in a single centre in Western Mexico. *Mycoses* 2021.
168. Shrestha O, Sharma Baral R. Covid-19 associated Mucormycosis: A case report. *J Nepal Health Res Counc* 2021; **19**(2): 414-6.
169. Kumar Gupta S, Jyotsana P, Singh A, Phuyal D, Allam P. Rhinocerebral Mucormycosis in a COVID-19 Patient from Nepal: A Case Report. *JNMA J Nepal Med Assoc* 2021; **59**(239): 703-5.
170. Buil JB, van Zanten ARH, Bentvelsen RG, et al. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. *Euro Surveill* 2021; **26**(23).
171. Mobeen H, Khan NU, Hassan M, et al. Orbital mucormycosis -post SARS-CoV-2 sequelae. *Brain Hemorrhages* 2021.

172. Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19 associated mucormycosis: a life-threatening complication in patients admitted with severe to critical COVID-19 from Pakistan. *Clin Microbiol Infect* 2021; **27**(11): 1704-7.
173. Alamin MA, Abdulgayoom M, Niraula S, Abdelmahmuod E, Ahmed AO, Danjuma MI. Rhino-orbital Mucormycosis as a complication of severe COVID-19 pneumonia. *IDCases* 2021; **26**: e01293.
174. Arana C, Cuevas Ramirez RE, Xipell M, et al. Mucormycosis associated with COVID-19 in two kidney transplant patients. *Transpl Infect Dis* 2021; **23**(4): e13652.
175. Lai CC, Wu CJ, Lee YC, Liu WL. COVID-19 associated with concomitant mucormycosis and aspergillosis. *J Microbiol Immunol Infect* 2021.
176. Malek I, Sayadi J, Lahiani R, et al. Acute bilateral blindness in a young Covid-19 patient with rhino-orbito-cerebral mucormycosis. *J Ophthalmic Inflamm Infect* 2021; **11**(1): 40.
177. Demirogu YZ, Odemis I, Oruc E, et al. [Two Case of Rhino-Orbito-Cerebral Mucormicosis Developed After COVID-19 Infection]. *Mikrobiyol Bul* 2021; **55**(4): 673-82.
178. Bayram N, Ozsaygili C, Sav H, et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. *Jpn J Ophthalmol* 2021; **65**(4): 515-25.
179. Sargin FA, M; Karaduman, S; Sungurtekin, H. Severe Rhinocerebral Mucormycosis Case Developed After COVID 19. *J Bacteriol Parasitol* 2021; **12**: 386.
180. Dilek A, Ozaras R, Ozkaya S, Sunbul M, Sen EI, Leblebicioglu H. COVID-19-associated mucormycosis: Case report and systematic review. *Travel Med Infect Dis* 2021; **44**: 102148.
181. Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. *Lancet Microbe* 2020; **1**(6): e245-e53.
182. Krishna V, Morjaria J, Jalandari R, Omar F, Kaul S. Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. *IDCases* 2021; **25**: e01172.
183. Placik DA, Taylor WL, Wnuk NM. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. *Radiol Case Rep* 2020; **15**(11): 2378-81.
184. Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. *Med Mycol Case Rep* 2021; **32**: 64-7.
185. Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. *Orbit* 2021: 1-4.
186. Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. *Ophthalmic Plast Reconstr Surg* 2021; **37**(2): e40-e80.
187. Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR. A Fatal Case of Rhizopus azygosporus Pneumonia Following COVID-19. *J Fungi (Basel)* 2021; **7**(3).
188. Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral Mucormycosis and COVID-19 Pneumonia. *J Med Cases* 2021; **12**(3): 85-9.
189. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. *Am J Emerg Med* 2021; **42**: 264 e5- e8.
190. Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature. *J Mycol Med* 2021; **31**(2): 101125.
191. Elhamamsy S, Bayer T, Al-Kaffas M, et al. Rhino-Orbital Cerebral Mucormycosis in Non-Diabetic Patients with COVID-19. *R I Med J (2013)* 2021; **104**(8): 19-21.
192. Khan N, Gutierrez CG, Martinez DV, Proud KC. A case report of COVID-19 associated pulmonary mucormycosis. *Arch Clin Cases* 2020; **7**(3): 46-51.
193. Souquett Gil M. Micólogos registran 4 casos de mucormicosis asociada al COVID-19 en Venezuela. 2021. https://efectococuyo.com/salud/hongo-negro-venezuela-mucormicosis-asociada-al-covid-19/ (accessed 16.11.2021 2021).
194. Benedetti MF, de Abreu MS, Cadena RC, et al. Invasive pulmonary aspergillosis and candidiasis in a critically ill patient with COVID-19. *J Mycol Med* 2022; **32**(2): 101251.

195. Seitz T, Hoepler W, Weseslindtner L, et al. Successful management of the first reported case in Austria of COVID-19 with ARDS. *Infection* 2020; **48**(4): 647-51.
196. Saeed NK, Al-Khawaja S, Alsalman J, Almusawi S, Albalooshi NA, Al-Biltagi M. Bacterial co-infection in patients with SARS-CoV-2 in the Kingdom of Bahrain. *World J Virol* 2021; **10**(4): 168-81.
197. de Almeida JNJ, Brandao IB, Francisco EC, et al. Axillary Digital Thermometers uplifted a multidrug-susceptible Candida auris outbreak among COVID-19 patients in Brazil. *Mycoses* 2021; **64**(9): 1062-72.
198. de Almeida JN, Jr., Francisco EC, Hagen F, et al. Emergence of Candida auris in Brazil in a COVID-19 Intensive Care Unit. *J Fungi (Basel)* 2021; **7**(3).
199. Silva DL, Lima CM, Magalhaes VCR, et al. Fungal and bacterial coinfections increase mortality of severely ill COVID-19 patients. *J Hosp Infect* 2021; **113**: 145-54.
200. Riche CVW, Cassol R, Pasqualotto AC. Is the Frequency of Candidemia Increasing in COVID-19 Patients Receiving Corticosteroids? *J Fungi (Basel)* 2020; **6**(4).
201. Nucci M, Barreiros G, Guimaraes LF, Deriquehem VAS, Castineiras AC, Nouer SA. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. *Mycoses* 2021; **64**(2): 152-6.
202. Zhang J, Lan P, Yi J, et al. Secondary bloodstream infection in critically ill patients with COVID-19. *J Int Med Res* 2021; **49**(12): 3000605211062783.
203. Sang L, Xi Y, Lin Z, et al. Secondary infection in severe and critical COVID-19 patients in China: a multicenter retrospective study. *Ann Palliat Med* 2021; **10**(8): 8557-70.
204. Rodriguez JY, Le Pape P, Lopez O, Esquea K, Labiosa AL, Alvarez-Moreno C. Candida auris: A Latent Threat to Critically Ill Patients With Coronavirus Disease 2019. *Clin Infect Dis* 2021; **73**(9): e2836-e7.
205. Flores B. Paciente infectado por Candida Auris falleció y estuvo ingresado en Hospital El Salvador, asegura médico Iván Solano. 2021. https://www.laprensagrafica.com/elsalvador/Advierten-primer-caso-por-infeccion-de-hongo-Candida-Auris-en-El-Salvador-20210222-0047.html (accessed 30.09.2021 2021).
206. Ramadan HK, Mahmoud MA, Aburahma MZ, et al. Predictors of Severity and Co-Infection Resistance Profile in COVID-19 Patients: First Report from Upper Egypt. *Infect Drug Resist* 2020; **13**: 3409-22.
207. Bretagne S, Sitbon K, Botterel F, et al. COVID-19-Associated Pulmonary Aspergillosis, Fungemia, and Pneumocystosis in the Intensive Care Unit: a Retrospective Multicenter Observational Cohort during the First French Pandemic Wave. *Microbiol Spectr* 2021; **9**(2): e0113821.
208. Buetti N, Ruckly S, de Montmollin E, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. *Intensive Care Med* 2021; **47**(2): 180-7.
209. Wiese‐Posselt M, Hinrichs C, Weikert B, et al. Infection control in two COVID‐19 patients with evidence for Candida Auris, Germany. 6th international conference on prevention & infection control (ICPIC 2021). Switzerland: Antimicrobial Resistance and Infection Control; 2021. p. 130.
210. Spiliopoulou A, Kolonitsiou F, Vrioni G, Tsoupra S, Lekkou A, Paliogianni F. Invasive Candida kefyr infection presenting as pyelonephritis in an ICU hospitalized COVID-19 patient: Case report and review of the literature. *J Mycol Med* 2021; **32**(2): 101236.
211. PAHO. Candida auris outbreaks in health care services in the context of the COVID-19 pandemic. www.iris.paho.org, 2021.
212. Szabo BG, Lakatos B, Bobek I, Szabo E, Szlavik J, Valyi-Nagy I. Invasive fungal infections among critically ill adult COVID-19 patients: First experiences from the national centre in Hungary. *J Mycol Med* 2021; **31**(4): 101198.
213. Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April-July 2020. *Emerg Infect Dis* 2020; **26**(11): 2694-6.

214. Rajni E, Singh A, Tarai B, et al. A High Frequency of Candida auris Blood Stream Infections in Coronavirus Disease 2019 Patients Admitted to Intensive Care Units, Northwestern India: A Case Control Study. *Open Forum Infect Dis* 2021; **8**(12): ofab452.
215. Agarwal M, Sachdeva M, Pal S, Shah H, Kumar RM, Banker A. Endogenous Endophthalmitis A Complication of COVID-19 Pandemic: A Case Series. *Ocul Immunol Inflamm* 2021; **29**(4): 726-9.
216. Niyas VK, Rahulan SD, Arjun R, Sasidharan A. ICU-acquired Candidemia in COVID-19 Patients: An Experience from a Tertiary Care Hospital in Kerala, South India. *Indian J Crit Care Med* 2021; **25**(10): 1207-8.
217. Shroff D, Narula R, Atri N, et al. Endogenous fungal endophthalmitis following intensive corticosteroid therapy in severe COVID-19 disease. *Indian J Ophthalmol* 2021; **69**(7): 1909-14.
218. Bhagali R, Prabhudesai NP, Prabhudesai MN. Post COVID-19 opportunistic candida retinitis: A case report. *Indian J Ophthalmol* 2021; **69**(4): 987-9.
219. Goyal M, Murthy SI, Annum S. Retinal manifestations in patients following COVID-19 infection: A consecutive case series. *Indian J Ophthalmol* 2021; **69**(5): 1275-82.
220. Sari AP, Darnindro N, Yohanes A, Mokoagow MI. Role of tocilizumab for concomitant systemic fungal infection in severe COVID-19 patient: Case report. *Medicine (Baltimore)* 2021; **100**(12): e25173.
221. Arastehfar A, Shaban T, Zarrinfar H, et al. Candidemia among Iranian Patients with Severe COVID-19 Admitted to ICUs. *J Fungi (Basel)* 2021; **7**(4).
222. Davoodi L, Faeli L, Mirzakhani R, Jalalian R, Shokohi T, Kermani F. Catastrophic Candida prosthetic valve endocarditis and COVID-19 comorbidity: A rare case. *Curr Med Mycol* 2021; **7**(2): 43-7.
223. Hebert J, Barr E, Magee C. Pacemaker-related Candida parapsilosis fungaemia in an immunosuppressed renal transplant recipient. *BMJ Case Rep* 2021; **14**(7).
224. Brikman S, Dori G, Kasher C, et al. Candida Bloodstream Infection, a Dire Complication in Hospitalized COVID-19 Patients: Three Cases from a Single Center in Northern Israel. *Isr Med Assoc J* 2021; **23**(10): 615-7.
225. Ayalon O, Cohen MJ, Orenbuch-Harroch E, Sviri S, van Heerden PV, Korem M. Invasive fungal infections in critically ill COVID-19 patients in a large tertiary university hospital in Israel. *J Crit Care* 2022; **69**: 154004.
226. Magnasco L, Mikulska M, Giacobbe DR, et al. Spread of Carbapenem-Resistant Gram-Negatives and Candida auris during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship? *Microorganisms* 2021; **9**(1).
227. Di Pilato V, Codda G, Ball L, et al. Molecular Epidemiological Investigation of a Nosocomial Cluster of C. auris: Evidence of Recent Emergence in Italy and Ease of Transmission during the COVID-19 Pandemic. *J Fungi (Basel)* 2021; **7**(2).
228. Hanson BM, Dinh AQ, Tran TT, et al. Candida auris Invasive Infections during a COVID-19 Case Surge. *Antimicrob Agents Chemother* 2021; **65**(10): e0114621.
229. Cultrera R, Barozzi A, Libanore M, et al. Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings. *Int J Environ Res Public Health* 2021; **18**(8).
230. Antinori S, Bonazzetti C, Gubertini G, et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? *Autoimmun Rev* 2020; **19**(7): 102564.
231. Mastrangelo A, Germinario BN, Ferrante M, et al. Candidemia in Coronavirus Disease 2019 (COVID-19) Patients: Incidence and Characteristics in a Prospective Cohort Compared With Historical Non-COVID-19 Controls. *Clin Infect Dis* 2021; **73**(9): e2838-e9.
232. Posteraro B, De Angelis G, Menchinelli G, et al. Risk Factors for Mortality in Adult COVID-19 Patients Who Develop Bloodstream Infections Mostly Caused by Antimicrobial-Resistant Organisms: Analysis at a Large Teaching Hospital in Italy. *J Clin Med* 2021; **10**(8).
233. Giacobbe DR, Battaglini D, Ball L, et al. Bloodstream infections in critically ill patients with COVID-19. *Eur J Clin Invest* 2020; **50**(10): e13319.
234. Yamamoto K, Nakamura K, Hagiya H, Otsuka F. Candidemia in COVID-19 treated with corticosteroids and tocilizumab. *Clin Case Rep* 2021; **9**(9): e04858.

235. Baba H, Kanamori H, Seike I, et al. Multiple Secondary Healthcare-Associated Infections Due to Carbapenem-Resistant Organisms in a Critically Ill COVID-19 Patient on Extensively Prolonged Venovenous Extracorporeal Membrane Oxygenation Support-A Case Report. *Microorganisms* 2021; **10**(1).
236. Allaw F, Kara Zahreddine N, Ibrahim A, et al. First Candida auris Outbreak during a COVID-19 Pandemic in a Tertiary-Care Center in Lebanon. *Pathogens* 2021; **10**(2).
237. Awada B, Alam W, Chalfoun M, Araj G, Bizri AR. COVID-19 and Candida duobushaemulonii superinfection: A case report. *J Mycol Med* 2021; **31**(3): 101168.
238. Villanueva-Lozano H, Treviño-Rangel RJ, González GM, et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. *Clin Microbiol Infect* 2021; **27**(5): 813-6.
239. Al-Hatmi AMS, Mohsin J, Al-Huraizi A, Khamis F. COVID-19 associated invasive candidiasis. *J Infect* 2021; **82**(2): e45-e6.
240. Moin S, Farooqi J, Rattani S, Nasir N, Zaka S, Jabeen K. C. auris and non-C. auris candidemia in hospitalized adult and pediatric COVID-19 patients; single center data from Pakistan. *Med Mycol* 2021.
241. Moin S, Farooqi J, Rattani S, Nasir N, Zaka S, Jabeen K. C. auris and non-C. auris candidemia in hospitalized adult and pediatric COVID-19 patients; single center data from Pakistan. *Med Mycol* 2021; **59**(12): 1238-42.
242. Miranda MA, Sousa SC, Montes VL. Post-COVID-19 neurocandidiasis. *Neurol Sci* 2021; **42**(11): 4419-20.
243. Omrani AS, Koleri J, Ben Abid F, et al. Clinical characteristics and risk factors for COVID-19-associated Candidemia. *Med Mycol* 2021; **59**(12): 1262-6.
244. Goravey W, Ali GA, Ali M, Ibrahim EB, Al Maslamani M, Abdel Hadi H. Ominous combination: COVID-19 disease and Candida auris fungemia-Case report and review of the literature. *Clin Case Rep* 2021; **9**(9): e04827.
245. Klimko N, Kozlova, O. In: D. S, editor.; 2022.
246. Al Argan RJ, Alqatari SG, Al Said AH, et al. Gastrointestinal perforation secondary to COVID-19: Case reports and literature review. *Medicine (Baltimore)* 2021; **100**(19): e25771.
247. Alfonso-Sanchez JL, Agurto-Ramirez A, Chong-Valbuena MA, et al. The Influence of Infection and Colonization on Outcomes in Inpatients With COVID-19: Are We Forgetting Something? *Front Public Health* 2021; **9**: 747791.
248. Mulet Bayona JV, Tormo Palop N, Salvador García C, et al. Impact of the SARS-CoV-2 Pandemic in Candidaemia, Invasive Aspergillosis and Antifungal Consumption in a Tertiary Hospital. *J Fungi (Basel)* 2021; **7**(6).
249. Segrelles-Calvo G, de SAGR, Llopis-Pastor E, et al. Candida spp. co-infection in COVID-19 patients with severe pneumonia: Prevalence study and associated risk factors. *Respir Med* 2021; **188**: 106619.
250. Gorospe-Sarasua L, Gallego-Rivera JI, Munoz-Molina GM, et al. [Delayed Candida Costochondritis and Spondylitis in a Post-COVID-19 Patient Previously Treated With Corticosteroids, Antibiotics, and Tocilizumab]. *Arch Bronconeumol* 2021; **57**: 48-50.
251. Moreno-Gomez LM, Esteban-Sinovas O, Garcia-Perez D, Garcia-Posadas G, Delgado-Fernandez J, Paredes I. Case Report: SARS-CoV-2 Infection-Are We Redeemed? A Report of Candida Spondylodiscitis as a Late Complication. *Front Med (Lausanne)* 2021; **8**: 751101.
252. Kaluarachchi S, Abeykoon M. A case of endogenous candida endophthalmitis with incidental cytomegalovirus infection and optic neuropathy in a patient recovered from severe COVID-19. *Indian J Ophthalmol* 2022; **70**(1): 323-6.
253. Komec S, Karabicak N, Ceylan AN, Gulmez A, Ozalp O. [Three Candida auris Case Reports from Istanbul, Turkey]. *Mikrobiyol Bul* 2021; **55**(3): 452-60.
254. Bolukbasi Y, Erkose Genc G, Orhun G, et al. [First Case of COVID-19 Positive Candida auris Fungemia in Turkey]. *Mikrobiyol Bul* 2021; **55**(4): 648-55.
255. Kayaaslan B, Eser F, Kaya Kalem A, et al. Characteristics of candidemia in COVID-19 patients; increased incidence, earlier occurrence and higher mortality rates compared to non-COVID-19 patients. *Mycoses* 2021; **64**(9): 1083-91.

256. Coskun AS, Durmaz SO. Fungal Infections in COVID-19 Intensive Care Patients. *Pol J Microbiol* 2021; **70**(3): 395-400.
257. Gorkem A, Sav H, Kaan O, Eren E. Coronavirus disease and candidemia infection: A case report. *J Mycol Med* 2021; **31**(3): 101155.
258. Senok A, Alfaresi M, Khansaheb H, et al. Coinfections in Patients Hospitalized with COVID-19: A Descriptive Study from the United Arab Emirates. *Infect Drug Resist* 2021; **14**: 2289-96.
259. White PL, Dhillon R, Healy B, Wise MP, Backs M. Reply to Rodriguez et al and Mastrangelo et al. *Clin Infect Dis* 2021; **73**(9): e2839-e41.
260. Clough N, Pringle E, Minakaran N, Schelenz S. Care for critically Ill patients with COVID-19: don't forget the eyes. *Eye (Lond)* 2021; **35**(4): 1054-5.
261. Diamond F. Battling C. Auris and COVID-19 at Same Time. 2021. https://www.infectioncontroltoday.com/view/battling-c-auris-and-covid-19-at-same-time (accessed 16.11.2021 2021).
262. Prestel C, Anderson E, Forsberg K, et al. Candida auris Outbreak in a COVID-19 Specialty Care Unit - Florida, July-August 2020. *MMWR Morb Mortal Wkly Rep* 2021; **70**(2): 56-7.
263. Kordalewska M, Guerrero KD, Garcia-Rubio R, et al. Antifungal Drug Susceptibility and Genetic Characterization of Fungi Recovered from COVID-19 Patients. *J Fungi (Basel)* 2021; **7**(7).
264. Bishburg E, Okoh A, Nagarakanti SR, Lindner M, Migliore C, Patel P. Fungemia in COVID-19 ICU patients, a single medical center experience. *J Med Virol* 2021; **93**(5): 2810-4.
265. Mirchin R, Czeresnia JM, Orner EP, Chaturvedi S, Murphy K, Nosanchuk JD. The Continuing Emergence of Candida blankii as a Pathogenic Fungus: A New Case of Fungemia in a Patient Infected with SARS-CoV-2. *J Fungi (Basel)* 2022; **8**(2).
266. Nori P, Cowman K, Chen V, et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. *Infect Control Hosp Epidemiol* 2021; **42**(1): 84-8.
267. Sturm LK, Saake K, Roberts PB, Masoudi FA, Fakih MG. Impact of COVID-19 pandemic on hospital onset bloodstream infections (HOBSI) at a large health system. *Am J Infect Control* 2022; **50**(3): 245-9.
268. Alataby H, Atemnkeng F, Bains SS, Kenne FM, Diaz K, Nfonoyim J. A COVID-19 Case Complicated by Candida dubliniensis and Klebsiella pneumoniae-Carbapenem-Resistant Enterobacteriaceae. *J Med Cases* 2020; **11**(12): 403-6.
269. Macauley P, Epelbaum O. Epidemiology and Mycology of Candidaemia in non-oncological medical intensive care unit patients in a tertiary center in the United States: Overall analysis and comparison between non-COVID-19 and COVID-19 cases. *Mycoses* 2021; **64**(6): 634-40.
270. Seagle EE, Jackson BR, Lockhart SR, et al. The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic. *Clin Infect Dis* 2022; **74**(5): 802-11.